KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Current Assets (2016 - 2026)

Gsk has reported Current Assets over the past 18 years, most recently at $23.9 billion for Q1 2026.

  • For Q1 2026, Current Assets rose 5.12% year-over-year to $23.9 billion; the TTM value through Mar 2026 reached $23.9 billion, up 5.12%, while the annual FY2025 figure was $23.3 billion, 6.76% up from the prior year.
  • Current Assets for Q1 2026 was $23.9 billion at Gsk, up from $23.3 billion in the prior quarter.
  • Over five years, Current Assets peaked at $68.2 billion in Q2 2022 and troughed at $20.5 billion in Q1 2022.
  • A 5-year average of $25.9 billion and a median of $23.6 billion in 2025 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: surged 177.93% in 2022 and later tumbled 64.52% in 2023.
  • Year by year, Current Assets stood at $24.4 billion in 2022, then fell by 5.01% to $23.1 billion in 2023, then decreased by 5.72% to $21.8 billion in 2024, then rose by 6.76% to $23.3 billion in 2025, then grew by 2.81% to $23.9 billion in 2026.
  • Business Quant data shows Current Assets for GSK at $23.9 billion in Q1 2026, $23.3 billion in Q4 2025, and $24.1 billion in Q3 2025.